Link Technologies secures exclusive license for ultra sensitive diagnostic probes
Deal marks the start of ongoing collaboration between Link and The University of Manchester
Link Technologies Ltd has announced an exclusive license deal with The University of Manchester Intellectual Property Limited (UMIP). Under the terms of the license for the University’s “exciplex” technology, Link will manufacture and sell highly sensitive exciplex-based diagnostic reagents worldwide. Exciplex technology offers ultra-biospecificity and significantly increased detection sensitivity over conventional systems due to negligible background signal. This license marks the start of a forward collaboration between Link and the University to develop the existing technology.
Honorary Professor Ken Douglas and Dr Elena Bichenkova, a Senior Lecturer in Medicinal Chemistry at the University of Manchester, have developed new exciplex diagnostic probes based on labelling oligonucleotides with exciplex partners that form excited-state complexes in close spatial proximity. Application of these modified oligonucleotides in diagnostic systems has been shown to discriminate DNA mutations at the level of PCR products and plasmid DNA. Professor Douglas commented: “This is a very exciting opportunity to bring together a University discovery base and this excellent company. The exciplex is a significant new area of science and we are pleased to have the expertise of Link Technologies to take this forward commercially for clinical benefit”.
Patents for this technology, covering all major market areas, are held by the University of Manchester and licensed to Link. Link Technologies has also secured the rights to any intellectual property arising from the collaboration with the University. No financial details of the agreement have been disclosed.
Topics
Organizations
Other news from the department science

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
More news from our other portals
Last viewed contents

Pocket-sized invention revolutionizes ability to detect harmful materials - The low-cost cellphone-based Raman spectrometer system can make identifications of unknown biological molecules within minutes
Oncofertility

Effective through AI in Transplantation Medicine: New Prediction Models for Disease Progression - Project network provides IT platform for clinical data integration, model development and validation
Cephalic_disorder
Vitamin_D
Obliquus_capitis_superior_muscle

Chromatin originated in ancient microbes one to two billion years ago - Genomic and proteomic analysis reveals that the regulatory role of chromatin is a eukaryotic innovation
'Radiolabeling' lets scientists track the breakdown of drugs
Eyespot_apparatus
Zollinger-Ellison_syndrome
T-tubule
